A new grant secured by the Lawrence Penn Chair of Bowel Cancer Research laboratory from the Cancer Institute NSW will enable further investigation into the prognostic contribution of immune cell infiltration in rectal cancer.
When Lawrence Penn was diagnosed with bowel cancer in 1985, the five-year relative survival rate was just 47 percent and life expectancy for newly diagnosed bowel cancer patients with advanced disease was just five months.
But as Lawrence celebrated his 96th birthday in December 2018, the bowel cancer landscape was gratefully a very different one.
Medical research plays a significant and critical role in improving the health and wellbeing of all Australians, allowing us to remain healthier for longer due to improved treatments and improved healthcare that results from this research.
Bowel Cancer Australia is the leading community-funded organisation dedicated to the prevention, early diagnosis, research, quality treatment and the best care for everyone affected by bowel cancer.
We fund research because it is the only way to discover a cure for bowel cancer.
Researching a cure for Australia's second deadliest cancer is to receive a major boost with $10.4 million to establish a professorial chair of bowel cancer research at the University of Sydney.
The majority of funding comes from national charity Bowel Cancer Australia, which has committed $6.4 million to establish the position and will be supported by additional funds of $4 million available to the University to advance research into bowel cancer.
Bowel Cancer Australia chairman Craig Jackson said that the establishment of the chair at the University of Sydney was the culmination of many years of effort by the Bowel Cancer Australia Board.